Overview
Pancreatic intraepithelial neoplasia (PanIN) represents a spectrum of neoplastic lesions that precede invasive pancreatic ductal adenocarcinoma (PDAC). These lesions are characterized by progressive architectural and cytological atypia, ranging from PanIN-1 (mild dysplasia) to PanIN-3 (severe dysplasia, often considered equivalent to carcinoma in situ). Early detection and accurate diagnosis of PanIN lesions are critical for understanding disease progression and guiding appropriate management strategies. While PanINs themselves are not typically symptomatic, their presence can indicate an increased risk of developing PDAC, necessitating vigilant surveillance and timely intervention. Advanced imaging techniques and endoscopic procedures play pivotal roles in diagnosing these lesions, particularly in the context of cystic lesions and solid masses within the pancreas.
Diagnosis
Imaging and Initial Assessment
The initial evaluation of pancreatic lesions often involves imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and endoscopic ultrasound (EUS). These techniques help in identifying the presence of solid masses or cystic lesions that may harbor PanIN lesions or progress to PDAC. EUS, in particular, offers high-resolution imaging and the capability for fine needle sampling, making it indispensable in the diagnostic workup.
Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) and Core Needle Biopsy (EUS-FNB/TTNB)
Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) and core needle biopsy (EUS-FNB/TTNB) are pivotal in achieving definitive diagnoses for pancreatic lesions. Studies have shown that EUS-FNB/TTNB exhibits a significantly higher diagnostic yield compared to traditional cytology methods. Specifically, EUS-FNB/TTNB demonstrated a diagnostic yield of 69%, markedly higher than cytology's 26% (P=.0017) [PMID:40414818]. This enhanced yield is particularly pronounced in cystic lesions, where EUS-FNB/TTNB achieved a specific diagnosis in 83.3% of cases versus only 16.7% for cytology (P=.0002) [PMID:40414818]. The higher diagnostic accuracy of EUS-FNB/TTNB is attributed to its ability to procure larger tissue samples, which are more informative for histopathological analysis.
Immunocytochemistry (ICC) in EUS-FNA Samples
To further refine the differentiation between PDAC and benign pancreatic tissue, the application of immunocytochemistry (ICC) markers is increasingly utilized. Markers such as Maspin, CK17, and Ki-67, when applied to cell blocks derived from EUS-FNA samples, enhance diagnostic precision. Maspin, for instance, is often downregulated in PDAC, while CK17 and Ki-67 can provide insights into cellular proliferation and differentiation status [PMID:34711007]. These markers help clinicians distinguish between benign and malignant processes, guiding appropriate management decisions.
Rebiopsy for Inconclusive Cases
In cases where initial EUS-FNA cytology results are inconclusive, rebiopsy using EUS-FNB/TTNB can be highly effective. Studies indicate that rebiopsy successfully provided definitive diagnoses in 9 out of 10 cases with previous inconclusive EUS-FNA cytology [PMID:40414818]. This underscores the importance of persistence in diagnostic efforts, especially when clinical suspicion remains high despite initial uncertainties.
Monitoring and Follow-Up
For patients with indeterminate or low-grade PanIN lesions, regular follow-up imaging (typically every 6-12 months) is recommended to monitor for any progression. EUS and MRI/magnetic resonance cholangiopancreatography (MRCP) are preferred due to their sensitivity in detecting subtle changes. If there is evidence of progression or high-grade dysplasia, more aggressive interventions such as surgical resection or neoadjuvant therapy may be considered.
Management
Preoperative Assessment and Neoadjuvant Therapy
A precise preoperative diagnosis facilitated by advanced techniques like EUS-FNAC is crucial for tailoring treatment strategies. Identifying patients with high-grade PanIN or early-stage PDAC who may benefit from neoadjuvant therapy is essential. Neoadjuvant therapy aims to reduce tumor size, improve resectability, and potentially enhance survival outcomes. Common regimens include combinations of gemcitabine-based chemotherapy or FOLFIRINOX (leucovorin, fluorouracil, irinotecan, oxaliplatin), tailored based on patient comorbidities and tumor characteristics.
Surgical Considerations
For patients diagnosed with high-grade PanIN or early-stage PDAC, surgical resection (e.g., pancreaticoduodenectomy or distal pancreatectomy) remains the cornerstone of curative treatment when feasible. The decision for surgery should be made in conjunction with multidisciplinary tumor boards to assess tumor stage, patient fitness, and potential for complete resection.
Post-Treatment Monitoring
Post-treatment monitoring involves regular follow-up with imaging (CT, MRI, EUS) and clinical assessments to detect recurrence or new lesions. The frequency of follow-up can range from every 3-6 months in the first year post-treatment, tapering off to annually thereafter, depending on the initial response and risk factors. Biomarker monitoring, such as CA 19-9 levels, may also be employed to gauge disease status and detect recurrence early.
Key Recommendations
References
1 Shafi S, Frankel WL, Li Z, Jones D, Krishna SG, Esnakula AK et al.. Endoscopic ultrasound-guided pancreatic core-needle/microforceps biopsy is a valuable diagnostic tool for pancreatic lesions: Experience from a large academic institution. American journal of clinical pathology 2025. link 2 Mamdouh MM, Okasha H, Shaaban HAM, Hafez NH, El-Gemeie EH. Role of Maspin, CK17 and Ki-67 Immunophenotyping in Diagnosing of Pancreatic Ductal Adenocarcinoma in Endoscopic Ultrasound-Guided Fine Needle Aspiration Cytology. Asian Pacific journal of cancer prevention : APJCP 2021. link
2 papers cited of 3 indexed.